Citi notes that the FDA said in a status report filed in a Texas court that it needs more time to determine if Eli Lilly’s (LLY) tirzepatide should remain off
Citi notes that the FDA said in a status report filed in a Texas court that it needs more time to determine if Eli Lilly’s (LLY) tirzepatide should remain off
A joint status report that was filed in the U.S. District Court for the Northern District of Texas states in part: “To assist FDA in its reevaluation of the challenged
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $1,000.00. Mohit Bansal has given
Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its release, announced a clinical collaboration with Eli Lilly (LLY)
אנליסט הביוטכנולוגיה ביגלר וד”ר ג’יאנקרלו מוסקול, פרופסור חבר במחלקה לאונקולוגיה רפואית של השד במרכז הסרטן MD Anderson, ידונו בנתוני EMBER-3 הקרובים מ-LLY. הם יחקור את הפוטנציאל שלו לשנות את הסטנדרט